C WorldWide Group Holding A S lifted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 1.4% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,307,035 shares of the biopharmaceutical company’s stock after purchasing an additional 58,216 shares during the period. Gilead Sciences comprises approximately 5.0% of C WorldWide Group Holding A S’s investment portfolio, making the stock its 8th largest holding. C WorldWide Group Holding A S’s holdings in Gilead Sciences were worth $348,956,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Sanders Capital LLC purchased a new stake in Gilead Sciences in the 3rd quarter worth about $427,585,000. Renaissance Technologies LLC increased its holdings in Gilead Sciences by 35.0% in the 2nd quarter. Renaissance Technologies LLC now owns 10,407,848 shares of the biopharmaceutical company’s stock worth $736,667,000 after acquiring an additional 2,700,600 shares during the last quarter. Vanguard Group Inc. increased its holdings in Gilead Sciences by 2.4% in the 2nd quarter. Vanguard Group Inc. now owns 92,841,960 shares of the biopharmaceutical company’s stock worth $6,571,355,000 after acquiring an additional 2,148,697 shares during the last quarter. The Manufacturers Life Insurance Company increased its holdings in Gilead Sciences by 50.0% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 6,191,622 shares of the biopharmaceutical company’s stock worth $438,244,000 after acquiring an additional 2,062,886 shares during the last quarter. Finally, BlackRock Inc. increased its holdings in Gilead Sciences by 1.9% in the 2nd quarter. BlackRock Inc. now owns 104,906,494 shares of the biopharmaceutical company’s stock worth $7,425,281,000 after acquiring an additional 1,937,031 shares during the last quarter. Institutional investors own 75.94% of the company’s stock.
Several equities research analysts recently weighed in on GILD shares. Berenberg Bank set a $96.00 price objective on Gilead Sciences and gave the stock a “buy” rating in a report on Thursday, October 19th. Royal Bank of Canada started coverage on Gilead Sciences in a report on Thursday, September 14th. They issued an “outperform” rating and a $94.00 price objective for the company. JPMorgan Chase & Co. set a $85.00 price objective on Gilead Sciences and gave the stock a “buy” rating in a report on Wednesday, October 25th. Credit Suisse Group reissued a “buy” rating and issued a $82.00 price objective on shares of Gilead Sciences in a report on Thursday, December 7th. Finally, Zacks Investment Research lowered Gilead Sciences from a “hold” rating to a “sell” rating in a report on Wednesday, December 27th. Two investment analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $85.03.
Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.13 by $0.14. The business had revenue of $6.51 billion during the quarter, compared to analyst estimates of $6.40 billion. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. The company’s quarterly revenue was down 13.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.75 EPS. equities research analysts expect that Gilead Sciences, Inc. will post 8.53 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which was paid on Thursday, December 28th. Stockholders of record on Friday, December 15th were given a dividend of $0.52 per share. The ex-dividend date of this dividend was Thursday, December 14th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.63%. Gilead Sciences’s dividend payout ratio (DPR) is presently 23.66%.
In other news, insider John F. Milligan sold 220,000 shares of Gilead Sciences stock in a transaction dated Monday, November 13th. The stock was sold at an average price of $72.88, for a total transaction of $16,033,600.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Gregg H. Alton sold 15,000 shares of Gilead Sciences stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $74.82, for a total value of $1,122,300.00. Following the sale, the executive vice president now owns 77,363 shares of the company’s stock, valued at approximately $5,788,299.66. The disclosure for this sale can be found here. In the last quarter, insiders have sold 461,666 shares of company stock valued at $34,072,567. Corporate insiders own 1.30% of the company’s stock.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
What are top analysts saying about Gilead Sciences? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Gilead Sciences and related companies.